On research, development and public production of new drugs
DOI:
https://doi.org/10.24215/26183188e040Keywords:
public drug production, pseudo-innovation in the pharmaceutical industry, drug costs, me too drugsAbstract
The pharmaceutical industry is no longer the great innovative industry today, as it was in the last century. The research based on “me too” drugs and the “greening” practices are a clear example of the abandonment of this place. On the other hand, it is the States that mainly finance the research that gives rise to the few radical innovations in the field of medicines. This work discusses this problem and how, leaving the last stages of research and development of new drugs and their production in the hands of the private pharmaceutical industry, has allowed the companies involved to prioritize their economic benefits and the profitability of their shareholders, relegating research and development in new treatments that can solve Public Health problems. It also discusses how the Public Production of Medicines and other policies could contribute to universal access and to solve Argentine health needs.
Downloads
Metrics
Published
How to Cite
Issue
Section
License
The authors whose texts are published in this Journal surrender their ownership rights in favour of the editor in a non exclusive manner, i.e. the authors can enter into other independent and additional contracts to publish their text, e.g. including it in an institutional repository, thematic or otherwise, publish it in a book, or others, as long as it is overtly stated that the work was first published in this Journal.
The responsibility for each published paper as regards its content relies exclusively on its authors, holding the editors harmless for any legal liabilities.
The texts of the Journal shall be published under the Creative Commons 4.0 BY-NC-SA license. Therefore, the editors are free to:
1) Share, copy and redistribute the material using any means or format.
2) Adapt, remix, transform and create from the material, under the following conditions:
a) Attribution — credit to this work must be given in an appropriate manner, providing a link to the license and indicating if changes have been made.
b) Non-Commercial Use — no use may be made of the published material for commercial purposes.
c) Share Equal — Authors remixing, transforming or creating from the material must distribute their contribution under the same license as the original.
